Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury

Michela Campolo, Akbar Ahmad, Rosalia Crupi, Daniela Impellizzeri, Rossana Morabito, Emanuela Esposito, Salvatore Cuzzocrea

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Traumatic brain injury (TBI) is a major cause of preventable death and morbidity in young adults. This complex condition is characterized by a significant blood-brain barrier leakage that stems from cerebral ischemia, inflammation, and redox imbalances in the traumatic penumbra of the injured brain. Recovery of function after TBI is partly through neuronal plasticity. In order to test whether combination therapy with melatonin and dexamethasone (DEX) might improve functional recovery, a controlled cortical impact (CCI) was performed in adult mice, acting as a model of TBI. Once trauma has occurred, combating these exacerbations is the keystone of an effective TBI therapy. The therapy with melatonin (10 mg/kg) and DEX (0.025 mg/kg) is able to reduce edema and brain infractions as evidenced by decreased 2,3,5-triphenyltetrazoliumchloride staining across the brain sections. Melatoninand DEX-mediated improvements in tissue histology shown by the reduction in lesion size and an improvement in apoptosis level further support the efficacy of combination therapy. The combination therapy also blocked the infiltration of astrocytes and reduced CCI-mediated oxidative stress. In addition, we have also clearly demonstrated that the combination therapy significantly ameliorated neurological scores. Taken together, our results clearly indicate that combination therapy with melatonin and DEX presents beneficial synergistic effects, and we consider it an avenue for further development of novel combination therapeutic agents in the treatment of TBI that are more effective than a single effector molecule.

Original languageEnglish (US)
Pages (from-to)291-301
Number of pages11
JournalJournal of Endocrinology
Volume217
Issue number3
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Melatonin
Dexamethasone
Therapeutics
Traumatic Brain Injury
Neuronal Plasticity
Recovery of Function
Brain Edema
Brain
Brain Ischemia
Blood-Brain Barrier
Astrocytes
Oxidation-Reduction
Young Adult
Cause of Death
Histology
Oxidative Stress
Apoptosis
Staining and Labeling
Inflammation
Morbidity

Keywords

  • Cell death
  • Dexamethasone
  • Inflammation
  • Melatonin
  • Motor function
  • TBI

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Campolo, M., Ahmad, A., Crupi, R., Impellizzeri, D., Morabito, R., Esposito, E., & Cuzzocrea, S. (2013). Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury. Journal of Endocrinology, 217(3), 291-301. https://doi.org/10.1530/JOE-13-0022

Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury. / Campolo, Michela; Ahmad, Akbar; Crupi, Rosalia; Impellizzeri, Daniela; Morabito, Rossana; Esposito, Emanuela; Cuzzocrea, Salvatore.

In: Journal of Endocrinology, Vol. 217, No. 3, 2013, p. 291-301.

Research output: Contribution to journalArticle

Campolo, M, Ahmad, A, Crupi, R, Impellizzeri, D, Morabito, R, Esposito, E & Cuzzocrea, S 2013, 'Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury', Journal of Endocrinology, vol. 217, no. 3, pp. 291-301. https://doi.org/10.1530/JOE-13-0022
Campolo, Michela ; Ahmad, Akbar ; Crupi, Rosalia ; Impellizzeri, Daniela ; Morabito, Rossana ; Esposito, Emanuela ; Cuzzocrea, Salvatore. / Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury. In: Journal of Endocrinology. 2013 ; Vol. 217, No. 3. pp. 291-301.
@article{a8bd2fb2eede4aeaaaa09e97ae3686f3,
title = "Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury",
abstract = "Traumatic brain injury (TBI) is a major cause of preventable death and morbidity in young adults. This complex condition is characterized by a significant blood-brain barrier leakage that stems from cerebral ischemia, inflammation, and redox imbalances in the traumatic penumbra of the injured brain. Recovery of function after TBI is partly through neuronal plasticity. In order to test whether combination therapy with melatonin and dexamethasone (DEX) might improve functional recovery, a controlled cortical impact (CCI) was performed in adult mice, acting as a model of TBI. Once trauma has occurred, combating these exacerbations is the keystone of an effective TBI therapy. The therapy with melatonin (10 mg/kg) and DEX (0.025 mg/kg) is able to reduce edema and brain infractions as evidenced by decreased 2,3,5-triphenyltetrazoliumchloride staining across the brain sections. Melatoninand DEX-mediated improvements in tissue histology shown by the reduction in lesion size and an improvement in apoptosis level further support the efficacy of combination therapy. The combination therapy also blocked the infiltration of astrocytes and reduced CCI-mediated oxidative stress. In addition, we have also clearly demonstrated that the combination therapy significantly ameliorated neurological scores. Taken together, our results clearly indicate that combination therapy with melatonin and DEX presents beneficial synergistic effects, and we consider it an avenue for further development of novel combination therapeutic agents in the treatment of TBI that are more effective than a single effector molecule.",
keywords = "Cell death, Dexamethasone, Inflammation, Melatonin, Motor function, TBI",
author = "Michela Campolo and Akbar Ahmad and Rosalia Crupi and Daniela Impellizzeri and Rossana Morabito and Emanuela Esposito and Salvatore Cuzzocrea",
year = "2013",
doi = "10.1530/JOE-13-0022",
language = "English (US)",
volume = "217",
pages = "291--301",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "Society for Endocrinology",
number = "3",

}

TY - JOUR

T1 - Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury

AU - Campolo, Michela

AU - Ahmad, Akbar

AU - Crupi, Rosalia

AU - Impellizzeri, Daniela

AU - Morabito, Rossana

AU - Esposito, Emanuela

AU - Cuzzocrea, Salvatore

PY - 2013

Y1 - 2013

N2 - Traumatic brain injury (TBI) is a major cause of preventable death and morbidity in young adults. This complex condition is characterized by a significant blood-brain barrier leakage that stems from cerebral ischemia, inflammation, and redox imbalances in the traumatic penumbra of the injured brain. Recovery of function after TBI is partly through neuronal plasticity. In order to test whether combination therapy with melatonin and dexamethasone (DEX) might improve functional recovery, a controlled cortical impact (CCI) was performed in adult mice, acting as a model of TBI. Once trauma has occurred, combating these exacerbations is the keystone of an effective TBI therapy. The therapy with melatonin (10 mg/kg) and DEX (0.025 mg/kg) is able to reduce edema and brain infractions as evidenced by decreased 2,3,5-triphenyltetrazoliumchloride staining across the brain sections. Melatoninand DEX-mediated improvements in tissue histology shown by the reduction in lesion size and an improvement in apoptosis level further support the efficacy of combination therapy. The combination therapy also blocked the infiltration of astrocytes and reduced CCI-mediated oxidative stress. In addition, we have also clearly demonstrated that the combination therapy significantly ameliorated neurological scores. Taken together, our results clearly indicate that combination therapy with melatonin and DEX presents beneficial synergistic effects, and we consider it an avenue for further development of novel combination therapeutic agents in the treatment of TBI that are more effective than a single effector molecule.

AB - Traumatic brain injury (TBI) is a major cause of preventable death and morbidity in young adults. This complex condition is characterized by a significant blood-brain barrier leakage that stems from cerebral ischemia, inflammation, and redox imbalances in the traumatic penumbra of the injured brain. Recovery of function after TBI is partly through neuronal plasticity. In order to test whether combination therapy with melatonin and dexamethasone (DEX) might improve functional recovery, a controlled cortical impact (CCI) was performed in adult mice, acting as a model of TBI. Once trauma has occurred, combating these exacerbations is the keystone of an effective TBI therapy. The therapy with melatonin (10 mg/kg) and DEX (0.025 mg/kg) is able to reduce edema and brain infractions as evidenced by decreased 2,3,5-triphenyltetrazoliumchloride staining across the brain sections. Melatoninand DEX-mediated improvements in tissue histology shown by the reduction in lesion size and an improvement in apoptosis level further support the efficacy of combination therapy. The combination therapy also blocked the infiltration of astrocytes and reduced CCI-mediated oxidative stress. In addition, we have also clearly demonstrated that the combination therapy significantly ameliorated neurological scores. Taken together, our results clearly indicate that combination therapy with melatonin and DEX presents beneficial synergistic effects, and we consider it an avenue for further development of novel combination therapeutic agents in the treatment of TBI that are more effective than a single effector molecule.

KW - Cell death

KW - Dexamethasone

KW - Inflammation

KW - Melatonin

KW - Motor function

KW - TBI

UR - http://www.scopus.com/inward/record.url?scp=84878776055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878776055&partnerID=8YFLogxK

U2 - 10.1530/JOE-13-0022

DO - 10.1530/JOE-13-0022

M3 - Article

C2 - 23532863

AN - SCOPUS:84878776055

VL - 217

SP - 291

EP - 301

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 3

ER -